| 1 |
33980760 | Effectiveness and Safety of Lipid-Lowering Drug Treatments in Japanese Patients with Familial Hypercholesterolemia: Familial Hypercholesterolemia Expert Forum (FAME) Study. | 2022 May 1 |
1 |
| 2 |
34374964 | The Differential Metabolomes in Cumulus and Mural Granulosa Cells from Human Preovulatory Follicles. | 2022 Apr |
1 |
| 3 |
34809444 | Posttranscriptional Regulation of the Human LDL Receptor by the U2-Spliceosome. | 2022 Jan 7 |
3 |
| 4 |
34809446 | PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Triggers Vascular Smooth Muscle Cell Senescence and Apoptosis: Implication of Its Direct Role in Degenerative Vascular Disease. | 2022 Jan |
1 |
| 5 |
34846648 | A novel low-density lipoprotein receptor variant in a Ukrainian patient: a case report and overview of the disease-causing low-density lipoprotein receptor variants associated to familial hypercholesterolemia. | 2022 Feb |
1 |
| 6 |
34871818 | Genetic mutations, regression of Achilles tendon thickness, and cardiovascular events among patients with familial hypercholesterolemia. | 2022 Jan |
1 |
| 7 |
35007650 | Associations of pro-protein convertase subtilisin-like kexin type 9, soluble low-density lipoprotein receptor and coronary artery disease: A case-control study. | 2022 Mar 1 |
3 |
| 8 |
35123858 | Search for familial hypercholesterolemia patients in an Italian community: A real-life retrospective study. | 2022 Mar |
2 |
| 9 |
35140212 | Caffeine blocks SREBP2-induced hepatic PCSK9 expression to enhance LDLR-mediated cholesterol clearance. | 2022 Feb 9 |
1 |
| 10 |
35162992 | Emerging Insights on the Diverse Roles of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) in Chronic Liver Diseases: Cholesterol Metabolism and Beyond. | 2022 Jan 19 |
1 |
| 11 |
35181275 | Clinical decision support for familial hypercholesterolemia (CDS-FH): Rationale and design of a cluster randomized trial in primary care. | 2022 May |
1 |
| 12 |
35221836 | Potential dual inhibitors of PCSK-9 and HMG-R from natural sources in cardiovascular risk management. | 2022 |
1 |
| 13 |
35276852 | Assessment of the Cholesterol-Lowering Effect of MOMAST®: Biochemical and Cellular Studies. | 2022 Jan 23 |
1 |
| 14 |
35323658 | The Emerging Roles of Intracellular PCSK9 and Their Implications in Endoplasmic Reticulum Stress and Metabolic Diseases. | 2022 Feb 26 |
2 |
| 15 |
35336039 | Computational Design and Biological Evaluation of Analogs of Lupin Peptide P5 Endowed with Dual PCSK9/HMG-CoAR Inhibiting Activity. | 2022 Mar 18 |
2 |
| 16 |
35386468 | Black TiO2 nanoprobe-mediated mild phototherapy reduces intracellular lipid levels in atherosclerotic foam cells via cholesterol regulation pathways instead of apoptosis. | 2022 Nov |
2 |
| 17 |
35390434 | Genetic variation and intestinal cholesterol absorption in humans: A systematic review and a gene network analysis. | 2022 Apr |
1 |
| 18 |
35409162 | The Activity of Ten Natural Extracts Combined in a Unique Blend to Maintain Cholesterol Homeostasis-In Vitro Model. | 2022 Mar 30 |
1 |
| 19 |
35409167 | Identification and New Indication of Melanin-Concentrating Hormone Receptor 1 (MCHR1) Antagonist Derived from Machine Learning and Transcriptome-Based Drug Repositioning Approaches. | 2022 Mar 30 |
2 |
| 20 |
35429393 | Motivating cascade testing for familial hypercholesterolemia: applying the extended parallel process model for clinician communication. | 2022 Apr 16 |
1 |
| 21 |
35432976 | Daily intake of up to two eggs for 11 weeks does not affect the cholesterol balance of Chinese young adults. | 2022 Apr |
1 |
| 22 |
35447021 | No association between LDL receptor and CETP genetic variants and atorvastatin response in Jordanian hyperlipidemic patients. | 2022 Apr 21 |
2 |
| 23 |
35467154 | An update on lipid apheresis for familial hypercholesterolemia. | 2022 Apr 25 |
2 |
| 24 |
35469449 | Lessons learned from the evinacumab trials in the treatment of homozygous familial hypercholesterolemia. | 2022 Jun |
1 |
| 25 |
35493299 | Cholesterol Metabolic Markers for Differential Evaluation of Patients with Hyperlipidemia and Familial Hypercholesterolemia. | 2022 |
5 |
| 26 |
35527125 | What characterizes event-free elderly FH patients? A comprehensive lipoprotein profiling. | 2022 Jul |
1 |
| 27 |
35533584 | Expression patterns of genes in steroidogenic, cholesterol uptake, and liver x receptor-mediated cholesterol efflux pathway regulating cholesterol homeostasis in natural and PGF2α induced luteolysis as well as early pregnancy in ovine corpus luteum. | 2022 May |
1 |
| 28 |
35565772 | Hempseed (Cannabis sativa) Peptide H3 (IGFLIIWV) Exerts Cholesterol-Lowering Effects in Human Hepatic Cell Line. | 2022 Apr 26 |
1 |
| 29 |
35585420 | Retinoic acid increases the cellular cholesterol predominantly in a mTOR-independent manner. | 2022 May 18 |
2 |
| 30 |
35599686 | Testosterone Deficiency Promotes Hypercholesteremia and Attenuates Cholesterol Liver Uptake via AR/PCSK9/LDLR Pathways. | 2022 |
1 |
| 31 |
32090592 | Are anti-inflammatory agents and nutraceuticals - novel inhibitors of PCSK9? | 2021 |
2 |
| 32 |
32875580 | Physiology and role of PCSK9 in vascular disease: Potential impact of localized PCSK9 in vascular wall. | 2021 Apr |
2 |
| 33 |
32991689 | PCSK9 and LRP5 in macrophage lipid internalization and inflammation. | 2021 Jul 27 |
3 |
| 34 |
33147992 | Novel PCSK9 (Proprotein Convertase Subtilisin Kexin Type 9) Variants in Patients With Familial Hypercholesterolemia From Cape Town. | 2021 Feb |
1 |
| 35 |
33222314 | PCSK9 inhibitors for COVID-19: an opportunity to enhance the antiviral action of interferon in patients with hypercholesterolaemia. | 2021 May |
1 |
| 36 |
33307067 | PCSK9: Associated with cardiac diseases and their risk factors? | 2021 Jun 15 |
1 |
| 37 |
33315477 | Lifelong Reduction in LDL (Low-Density Lipoprotein) Cholesterol due to a Gain-of-Function Mutation in LDLR. | 2021 Feb |
6 |
| 38 |
33342622 | The Effect of Statins in Children and Adolescents With Familial Hypercholesterolemia: A Systematic Review. | 2021 May-Jun |
1 |
| 39 |
33394716 | Recent insights into low-density lipoprotein metabolism and therapy. | 2021 Mar 1 |
1 |
| 40 |
33461934 | Prognostic impact of cascade screening for familial hypercholesterolemia on cardiovascular events. | 2021 Mar-Apr |
2 |
| 41 |
33497862 | LDL-cholesterol lowering and clinical outcomes in hypercholesterolemic subjects with and without a familial hypercholesterolemia phenotype: Analysis from the secondary prevention 4S trial. | 2021 Mar |
1 |
| 42 |
33512150 | Engineered EGF-A Peptides with Improved Affinity for Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9). | 2021 Feb 19 |
1 |
| 43 |
33513160 | Genome-scale CRISPR screening for modifiers of cellular LDL uptake. | 2021 Jan |
1 |
| 44 |
33515402 | Patterns and tempo of PCSK9 pseudogenizations suggest an ancient divergence in mammalian cholesterol homeostasis mechanisms. | 2021 Feb |
1 |
| 45 |
33515861 | On the possible existence of a liver LDL-ostat, and its malfunctioning in familial hypercholesterolemia. | 2021 Feb |
3 |
| 46 |
33548684 | The polarized localization of lipoprotein receptors and cholesterol transporters in the syncytiotrophoblast of the placenta is reproducible in a monolayer of primary human trophoblasts. | 2021 Feb |
2 |
| 47 |
33606190 | Potentiating CD8+ T cell antitumor activity by inhibiting PCSK9 to promote LDLR-mediated TCR recycling and signaling. | 2021 Apr |
3 |
| 48 |
33647772 | Development of a novel, fully human, anti-PCSK9 antibody with potent hypolipidemic activity by utilizing phage display-based strategy. | 2021 Mar |
2 |
| 49 |
33716107 | Existing and emerging therapies for the treatment of familial hypercholesterolemia. | 2021 |
4 |
| 50 |
33757439 | Hepatic expression of cholesterol regulating genes favour increased circulating low-density lipoprotein in HIV infected patients with gallstone disease: a preliminary study. | 2021 Mar 23 |
1 |